SCHEMBL563139

SCHEMBL563139

CCCCCc1cc(NCC(C)(C)O)c(N)c(N(Cc2ccc(OC)cc2)Cc2ccc(OC)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
USP2 O75604 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
APAF1 O14727 1/20 0.36
NR1I2 O75469 1/20 0.36
HSP90AA1 P07900 1/20 0.36
IDE P14735 1/20 0.36
UBE2N P61088 1/20 0.36
PTGS2 P35354 1/20 0.36
TLR7 Q9NYK1 4/20 0.35
TLR8 Q9NR97 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340349 0.85 NCF1 (0.47) HRH2HRH3CASP3SENP8SENP7
SCHEMBL563121 0.84 KDM4E (0.38) CASP3SENP8SENP7SENP6USP2
SCHEMBL4766984 0.83 TLR7 (0.40) HRH2HRH3TLR7PLK1PLK3
SCHEMBL562970 0.80 SLC2A1 (0.43) LMNATP53
SCHEMBL562449 0.75 TLR7 (0.40) HRH2HRH3CASP3SENP8SENP7
SCHEMBL31260428 0.72 HTT (0.41) LMNATSHRTP53MAPTSMN1; SMN2
SCHEMBL3178520 0.71 APP (0.46) USP2LMNAMAPTSMN1; SMN2NOS1
SCHEMBL3338086 0.71 PTGS2 (0.38) PTGS2CHRM1HTR2AMCHR1
SCHEMBL563646 0.70 KDM4E (0.39) MAPTSMN1; SMN2
SCHEMBL3339765 0.70 EGFR (0.46) LMNATLR7PLK1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 HRH2 24/4885HRH3 23/4885CASP3 1404/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 HRH2 27/4885HRH3 24/4885CASP3 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.